001     136833
005     20240229105102.0
024 7 _ |a 10.1002/ijc.31404
|2 doi
024 7 _ |a pmid:29582423
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:34939654
|2 altmetric
037 _ _ |a DKFZ-2018-01271
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Wirthschaft, Peter
|0 P:(DE-He78)7f9dda5a1b9a9ffc384598e80ade05f9
|b 0
|e First author
245 _ _ |a A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
260 _ _ |a Bognor Regis
|c 2018
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660211374_22214
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The Peroxiredoxin 1 (PRDX1) gene maps to chromosome arm 1p and is hemizygously deleted and epigenetically silenced in isocitrate dehydrogenase 1 or 2 (IDH)-mutant and 1p/19q-codeleted oligodendroglial tumors. In contrast, IDH-wildtype astrocytic gliomas including glioblastomas mostly lack epigenetic silencing and express PRDX1 protein. In our study, we investigated how PRDX1 contributes to the infiltrative growth of IDH-wildtype gliomas. Focusing on p38α-dependent pathways, we analyzed clinical data from 133 patients of the NOA-04 trial cohort to look for differences in the gene expression profiles of gliomas with wildtype or mutant IDH. Biochemical interaction studies as well as in vitro and ex vivo migration studies were used to establish a biological role of PRDX1 in maintaining pathway activity. Whole-brain high-resolution ultramicroscopy and survival analyses of pre-clinical mouse models for IDH-wildtype gliomas were then used for in vivo confirmation. Based on clinical data, we found that the absence of PRDX1 is associated with changes in the expression of MET/HGF signaling components. PRDX1 forms a heterodimer with p38α mitogen-activated protein kinase 14 (MAPK14), stabilizing phospho-p38α in glioma cells. This process amplifies hepatocyte growth factor (HGF)-mediated signaling and stimulates actin cytoskeleton dynamics that promote glioma cell migration. Whole-brain high-resolution ultramicroscopy confirms these findings, indicating that PRDX1 promotes glioma brain invasion in vivo. Finally, reduced expression of PRDX1 increased survival in mouse glioma models. Thus, our preclinical findings suggest that PRDX1 expression levels may serve as a molecular marker for patients who could benefit from targeted inhibition of MET/HGF signaling.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Bode, Julia
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Simon, Anika
|0 P:(DE-He78)2606ee60bf1453fe270da85b76dda50b
|b 2
700 1 _ |a Hoffmann, Elisa
|0 P:(DE-HGF)0
|b 3
700 1 _ |a van Laack, Rebecca
|0 P:(DE-He78)3c5a3c6d483c1f504214adb52d8e7e88
|b 4
700 1 _ |a Krüwel, Thomas
|0 P:(DE-He78)d9984bb7c7ce85fffd8c63899fb1d7fa
|b 5
700 1 _ |a Dietrich, Fabio
|0 P:(DE-He78)268bacdaa8869513e9bbb14f2b838ada
|b 6
700 1 _ |a Bucher, Delia
|0 P:(DE-He78)adaa691c494eb859fc6bb9af8949415c
|b 7
700 1 _ |a Hahn, Artur
|b 8
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 9
700 1 _ |a Breckwoldt, Michael
|0 P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303
|b 10
|u dkfz
700 1 _ |a Kurz, Felix T
|b 11
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 12
700 1 _ |a Fischer, Bernd
|0 P:(DE-He78)5e8c9e37b2ec5e928b6170cf9ecf9770
|b 13
700 1 _ |a Dross, Nicolas
|b 14
700 1 _ |a Ruiz de Almodovar, Carmen
|b 15
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 16
|u dkfz
700 1 _ |a Herold-Mende, Christel
|b 17
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 18
700 1 _ |a Boulant, Steeve
|0 P:(DE-He78)4658b59d5b4e54b919fc63ab1213c78f
|b 19
700 1 _ |a Wiestler, Benedikt Paul Otmar
|0 P:(DE-He78)2d0c564eca775a62ff86225f7717af12
|b 20
700 1 _ |a Reifenberger, Guido
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 22
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 23
700 1 _ |a Tews, Björn
|0 P:(DE-He78)a33ae52a1d80b847405db3ab83b9e90d
|b 24
|e Last author
773 _ _ |a 10.1002/ijc.31404
|g Vol. 143, no. 5, p. 1176 - 1187
|0 PERI:(DE-600)1474822-8
|n 5
|p 1176 - 1187
|t International journal of cancer
|v 143
|y 2018
|x 0020-7136
909 C O |p VDB
|o oai:inrepo02.dkfz.de:136833
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)7f9dda5a1b9a9ffc384598e80ade05f9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)2606ee60bf1453fe270da85b76dda50b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)3c5a3c6d483c1f504214adb52d8e7e88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d9984bb7c7ce85fffd8c63899fb1d7fa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)268bacdaa8869513e9bbb14f2b838ada
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)adaa691c494eb859fc6bb9af8949415c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)5e8c9e37b2ec5e928b6170cf9ecf9770
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)4658b59d5b4e54b919fc63ab1213c78f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)2d0c564eca775a62ff86225f7717af12
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)a33ae52a1d80b847405db3ab83b9e90d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2015
920 1 _ |0 I:(DE-He78)V077-20160331
|k V077
|l AG Molekulare Mechanismen der Tumorzell-Invasion
|x 0
920 1 _ |0 I:(DE-He78)G370-20160331
|k G370
|l KKE Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
920 1 _ |0 I:(DE-He78)F140-20160331
|k F140
|l NWG Infection and Immune Sensing Dynamics
|x 3
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 4
920 1 _ |0 I:(DE-He78)D170-20160331
|k D170
|l Neuroimmunologie und Hirntumorimmunologie
|x 5
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 6
920 1 _ |0 I:(DE-He78)B210-20160331
|k B210
|l B210 Evolution und Früherkennung
|x 7
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 8
920 1 _ |0 I:(DE-He78)L401-20160331
|k L401
|l DKTK Essen
|x 9
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l B060 Molekulare Genetik
|x 10
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)V077-20160331
980 _ _ |a I:(DE-He78)G370-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)F140-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)D170-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)B210-20160331
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a I:(DE-He78)L401-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21